Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

…, M Abdel-Rahman, X Wang, AD Levine, JK Rho… - Nature …, 2012 - nature.com
Human non–small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently
respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, …

RETRACTED ARTICLE: EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

…, H Alder, G Condorelli, JA Engelman, M Ono, JK Rho… - Nature medicine, 2012 - nature.com
The involvement of the MET oncogene in de novo and acquired resistance of non-small cell
lung cancers (NSCLCs) to tyrosine kinase inhibitors (TKIs) has previously been reported, …

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell …

JK Rho, YJ Choi, JK Lee, BY Ryoo, SH Yang, CH Kim… - Lung cancer, 2009 - Elsevier
Epithelial to mesenchymal transition (EMT) has been reported to be related with reduced
sensitivity to EGFR tyrosine kinase (EGFR-TK) inhibitors. We performed this study to investigate …

[HTML][HTML] Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer

…, SJ Nam, CM Choi, M Yun, JC Lee, JK Rho - … & molecular medicine, 2019 - nature.com
Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway
blockade is a promising new cancer therapy. Although PD-1/PD-L1 treatment has yielded …

Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells

MJ Jung, JK Rho, YM Kim, JE Jung, YB Jin, YG Ko… - Oncogene, 2013 - nature.com
The hypothesis of cancer stem cells has been proposed to explain the therapeutic failure in
a variety of cancers including lung cancers. Previously, we demonstrated acquisition of …

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

JH Chung, JK Rho, X Xu, JS Lee, HI Yoon, CT Lee… - Lung cancer, 2011 - Elsevier
BACKGROUND: Epithelial-to-mesenchymal transition (EMT), which was related with an
acquired resistance to gefitinib, was found in the A549 lung cancer cell line. However, the …

MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation

JK Rho, YJ Choi, SY Kim, TW Kim, EK Choi, SJ Yoon… - Cancer research, 2014 - AACR
In non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations,
acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKI) can occur through a …

[HTML][HTML] Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation

HR Kim, WS Kim, YJ Choi, CM Choi, JK Rho, JC Lee - Molecular oncology, 2013 - Elsevier
Epithelial-mesenchymal transition (EMT) is associated with reduced sensitivity to many
chemotherapeutic drugs, including EGFR tyrosine kinase inhibitors. Here, we investigated if this …

p53 enhances Gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non–small cell lung cancer

JK Rho, YJ Choi, BY Ryoo, III Na, SH Yang, CH Kim… - Cancer research, 2007 - AACR
Abstract Treatment with gefitinib, a specific inhibitor of epidermal growth factor receptor
tyrosine kinase (EGFR-TK), has resulted in dramatic responses in some patients with non–small …

Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1. 4

…, M Yun, YS Yi, CW Lee, SY Kim, JC Lee, JK Rho - Cancer letters, 2020 - Elsevier
Tumor-derived exosomes (TEXs) contain enriched miRNAs that act as novel non-invasive
biomarkers for cancer diagnosis and play a role in cancer progression. We investigated the …